|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 169.2 USD | +0.70% |
|
+0.68% | +9.18% |
| 07-12 | AbbVie Submits FDA, EMA Applications for Upadacitinib to Treat Giant Cell Arteritis | MT |
| 07-12 | AbbVie Seeks U.S., Europe OK of Rinvoq in Giant Cell Arteritis | DJ |
(Reuters) - Pharmaceutical companies AbbVie and Eli Lilly have withdrawn from Britain's voluntary medicines pricing agreement, an industry body said on Monday.
Companies are increasingly arguing that it is no longer possible to justify the UK's "voluntary scheme" to global boardrooms and investors as repayment rates in 2023 have surged to 26.5% of revenue, the Association of the British Pharmaceutical Industry said.
(Reporting by Radhika Anilkumar in Bengaluru; Editing by Sherry Jacob-Phillips)
| 1st Jan change | Capi. | |
|---|---|---|
| +9.18% | 297B | |
| +61.53% | 856B | |
| +38.95% | 631B | |
| -3.66% | 359B | |
| +15.06% | 325B | |
| +5.89% | 234B | |
| +16.53% | 226B | |
| +15.67% | 177B | |
| +2.47% | 165B | |
| +2.41% | 126B |
ABBVIE INC. 
